ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00167999
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : March 15, 2007
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary:
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Condition or disease Intervention/treatment
Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections Drug: piperacillin-tazobactam

Study Type : Observational
Enrollment : 200 participants
Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
Study Start Date : February 2005






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible patients of either sex, 15 years of age or older
  • Patients who are admitted to the department of hematology and oncology
  • Provide written informed consent

Exclusion Criteria:

  • Patients who have hypersensitivity to β-lactam antibiotics
  • Female who are pregnant or breast-feeding
  • Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167999


Locations
Korea, Republic of
Seoul, Korea, Republic of, 133-792
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier: NCT00167999     History of Changes
Other Study ID Numbers: 0910X-101676
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: March 15, 2007
Last Verified: March 2007

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Bacterial Infections

Additional relevant MeSH terms:
Klebsiella Infections
Infection
Communicable Diseases
Bacterial Infections
Gram-Positive Bacterial Infections
Escherichia coli Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Tazobactam
Penicillanic Acid
Piperacillin
Piperacillin, tazobactam drug combination
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action